In 59 participants with idiopathic overactive bladder, 100 U incobotulinumtoxinA was non-inferior to 100 U onabotulinumtoxinA for reducing urgency incontinence episodes at 2-6 weeks, though daytime voids and PGI-I improved more with onabotulinumtoxinA.
RCTn = 59
Trikhacheva et al. IncobotulinumtoxinA Versus OnabotulinumtoxinA for Treatment of Overactive Bladder Syndrome: A Randomized Single-blinded Non-inferiority Trial